IL2RB Remodels the Immune Microenvironment and Promotes the Progression of Esophageal Squamous Cell Carcinoma.

Objective: Esophageal squamous cell carcinoma (ESCA) is a prevalent malignant tumor with poor prognosis. Interleukin 2 receptor beta (IL2RB) has been implicated in various cancers; however, its role in ESCC remains unclear.

Methods: We analyzed IL2RB expression in clinical samples and cell lines.

DCTPP1 is Transcriptionally Activated by FOXA1 to Affect Cisplatin Sensitivity in Triple-Negative Breast Cancer via Suppression of Ferroptosis.

Triple negative breast cancer (TNBC) leads to significant global death due to the therapeutic failure such as the development of chemoresistance. The objective of this study was to discover the potential targets inhibiting cancer progression and enhancing cisplatin sensitivity in TNBC. Forkhead Box Protein A1 (FOXA1) and deoxycytidine triphosphate pyrophosphatase 1 (DCTPP1) expression was detected via real-time quantification PCR and western blotting.

Targeting HLA-E in Lung Cancer: The Therapeutic Potential of IRF5-Engineered M1-Macrophage-Derived Exosomes.

Immunotherapy is a pivotal approach in the treatment of lung cancer. Although HLA-E is a potential target for tumor immunotherapy, its role in lung cancer remains unclear. Previous studies have identified the transcription factor IRF5 as a characteristic gene of M1-like macrophages, highlighting its crucial role in promoting antitumor immune responses.

Keratin-15 high expression links with lymph node metastasis and poor survival prognosis in epithelial ovarian cancer patients.

Background: Keratin-15 (KRT15) involves in the progression and owns prognostic values in several solid cancers, whose clinical role in epithelial ovarian cancer (EOC) is rarely reported. This study aimed to identify the association of KRT15 expression with tumor features and survival of surgical EOC patients.

Methods: Formalin-fixed paraffin-embedded tumor tissues of 140 EOC patients who underwent tumor resection were retrieved for KRT15 determination using immunohistochemistry (IHC) assay.

Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation.

Sorafenib is a small-molecule multi-kinase inhibitor approved by FDA as an oral agent for the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma. However, unresponsiveness and acquired resistance are commonly observed, which hinder the clinical use of sorafenib. As combination therapy is a promising approach to improve its efficacy, we investigated if sorafenib and luteolin combination is effective in killing human HCC cells.

Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition.

The small molecule multi-kinase inhibitor sorafenib has become the standard systemic treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell carcinoma. Similar to other kinase inhibitors, drug resistance hinders its clinical use; thus, combination therapy to improve sorafenib sensitivity is a promising approach. The present study shows for the first time that the combination of sorafenib and wogonin exerts a significant potentiation of cytotoxicity in a number of human HCC cell lines in a dose-dependent manner.